Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer

About this update from Charles River Laboratories International, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1245,"height":326,"url":"https://media.zenfs.com/en/business-wire.com/cb1b9af46bc5a79d07a564fba229c1e4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tsnmRhbnv1UusDMpWcElSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cb1b9af46bc5a79d07a564fba229c1e4","width":960,"height":251},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0M0xaNXMadt1nu2kgTw3Vg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/cb1b9af46bc5a79d07a564fba229c1e4","width":1200,"height":314}},"lazy":false},{"type":"text","content":"WILMINGTON, Mass., September 11, 2025--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) has recently announced two strategic collaborations across its contract development and manufacturing organization (CDMO), aimed at advancing novel oncology research and development. These collaborations include forming an alliance with the Parker Institute for Cancer Immunotherapy and supporting a streamlined manufacturing process for Children’s Hospital Los Angeles’ Phase I Clinical Trials.","length":510,"tagName":"p"},{"type":"text","content":"Across its portfolio, Charles River is dedicated to advancing oncology research and leveraging new technologies and techniques to enhance the ability to deliver life-changing therapeutics to patients.","length":200,"tagName":"p"},{"type":"text","content":"Alliance with the Parker Institute for Cancer ImmunotherapyCharles River has formed a strategic alliance with the Parker Institute for Cancer Immunotherapy (PICI), a research institute that brings together researchers, nonprofits, and industries to get treatments to patients faster. As part of the strategic alliance, PICI network members and their companies will have access to Charles River’s unique portfolio of preclinical drug discovery and development services, ranging from early discovery to manufacturing. As an established cell and gene therapy (C&GT) CDMO and preclinical research partner, Charles River’s integrated approach combines research and development with biologics testing and manufacturing to maximize knowledge transfer, reduce bottlenecks, and accelerate drug development.","...

More updates from Charles River Laboratories International, Inc.